COX-2 Advisory Committee Review Will Include New Celebrex Safety Data
• By Lee Kalowski
Committee will also “explore ways of further evaluation” of the safety of Pfizer’s Bextra and COX-2s approved in Europe, such as Merck’s Arcoxia. FDA also expects discussion of broader NSAID category, at least for “context.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
